Strength in numbers - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Strength in numbers


Pharmaceutical Technology Europe
Volume 21, Issue 9


Fedra Pavlou
Merger, union, alliance, partnership, collaboration: five words that ultimately suggest the strengthening of something. Every company, no matter how large or small, must undertake at least one of these strategies to secure its longevity.

Indeed, no one can escape the frenzy of activity that has been taking place in the pharmaceutical industry lately. Such unions have, of course, been commonplace; however, it's been quite interesting to see pharma's response to the threats it currently faces, including, amongst others, the economic downturn, dry development pipelines and generic competition. The reaction of these already giant corporations has been to form alliances to grow an existing division, to diversify, to shed an underperforming unit, to secure a solid pipeline, and so on. Whatever the secondary reason, the primary reason has always been to secure growth, to strengthen, to improve and to survive.

At Pharmaceutical Technology Europe, we too have undertaken such a union; we have united with our US colleagues at Pharmaceutical Technology to bring our readers a tool that we believe is the best online resource for pharmaceutical manufacturing professionals. We hope that you agree with us!

Launched last month, the new http://www.pharmtech.com/ covers developments from around the world in formulation, outsourcing, drug delivery, ingredients, regulatory, testing, packaging and IT. As well as providing news and analysis, the site allows you to interact with us and your peers on Pharma Tech Talk, access archives of peer-reviewed content and features, take part in surveys and polls, search suppliers, read interviews with industry leaders, search for careers, watch webcasts, listen to podcasts, and access our significant library of white papers. I could go on, but I hope all of these are reason enough to entice you to visit our brand new website and to keep coming back!

I would welcome your comments and suggestions on the new http://www.pharmtech.com/ so please do feel free to email me with your thoughts. After all, this website is for you.




Many thanks and best wishes,

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology Europe,
Click here